Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by Evolutionary Tree Capital Management LLC

Evolutionary Tree Capital Management LLC increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 17.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,700 shares of the company's stock after buying an additional 1,588 shares during the period. Krystal Biotech accounts for about 1.7% of Evolutionary Tree Capital Management LLC's holdings, making the stock its 25th largest holding. Evolutionary Tree Capital Management LLC's holdings in Krystal Biotech were worth $1,676,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in KRYS. Wellington Management Group LLP increased its stake in Krystal Biotech by 15.1% during the 3rd quarter. Wellington Management Group LLP now owns 12,680 shares of the company's stock valued at $2,308,000 after purchasing an additional 1,660 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock valued at $107,714,000 after acquiring an additional 11,411 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its holdings in Krystal Biotech by 198.2% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 9,010 shares of the company's stock worth $1,640,000 after acquiring an additional 5,989 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Krystal Biotech in the 3rd quarter valued at approximately $40,000. Finally, Franklin Resources Inc. boosted its stake in Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock valued at $43,774,000 after purchasing an additional 62,178 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Performance

KRYS stock traded up $2.87 on Thursday, hitting $167.57. 73,980 shares of the company's stock were exchanged, compared to its average volume of 294,742. The stock has a market cap of $4.84 billion, a P/E ratio of 55.98 and a beta of 0.75. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34. The firm has a 50 day moving average price of $174.45 and a two-hundred day moving average price of $172.08.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm's revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.30 earnings per share. Sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on KRYS shares. Jefferies Financial Group started coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Friday, February 28th. Finally, Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech has a consensus rating of "Buy" and an average price target of $220.00.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).